News Mar 21, 2025
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News Mar 19, 2025
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
News Mar 07, 2025
DCAT Week 2025 — The Premier Event Connecting Biotech and Pharmaceutical Industries
DCAT Week is the premier annual event for the biotechnology and pharmaceutical manufacturing value chain. With senior decision-makers in attendance, it provides a unique platform for healthcare companies of all sizes to conduct high-level business meetings and foster strategic partnerships.
News Mar 07, 2025
Porton Wins Outsourced Pharma 2025 CDMO Leadership Award
In March 2025, Porton Pharma Solutions Ltd. was honored with the "Global Small Molecule API Award" at the 14th Outsourced Pharma CDMO Leadership Awards, recognizing its exceptional end-to-end services across the global small molecule drug lifecycle. This award reaffirms Porton's outstanding performance in the CDMO sector for pharmaceutical R&D and manufacturing worldwide.
NewslettersMar 06, 2025
Porton Newsletter - Jan. to Feb. 2025 Recap
Technical Enabling Technical Solutions for PROTAC Drugs Successful GMP Drug Product Delivery by Porton Biologics and Conjugates Platform
News Feb 28, 2025
Porton to Showcase Cutting-edge Innovations at BIO-Europe Spring 2025
Porton Pharma Solutions will once again participate in BIO-Europe Spring 2025, held from March 17th to 19th, at booth #87.
News Feb 13, 2025
Join Porton at Leading Industry Conferences to Explore Innovations and Network with Experts
Porton Pharma Solutions is thrilled to announce its participation in several major industry events across the globe during the first and second quarters of 2025. As a leading end-to-end integrated CDMO company, Porton boasts globally advanced technology platforms and extensive project delivery experience in small molecules, peptides and oligonucleotides, ADCs (including antibodies, payload-linkers, conjugation, and drug product filling), and Advanced Therapy Medicinal Products.
News Jan 28, 2025
Our Incredible Journey in 2024
Under open skies, the years pass endlessly. As the sun rises, Porton welcomes a new year with sincerity and hope. Reflecting on 2024, we faced challenges together, standing strong and united, achieving great heights.
News Jan 14, 2025
Successful GMP Drug Product Delivery by Porton Biologics and Conjugates Platform
Recently, the Porton Biologics and Conjugates Platform successfully completed the GMP contract manufacturing of three batches of sterile drug products for a client at our R&D and production facility in Pudong, Shanghai. This milestone marks a significant step forward for our Biologics and Conjugates CDMO platform—a testament to our unwavering commitment to quality and reliability.
